Therapy News and Research

RSS

Quick tips to avoid carbon monoxide poisoning

Temperatures in the next few days are predicted to be the coldest of the winter so far, and people using space heaters to get some extra warmth into their living and working spaces need to be aware of a potential "silent killer" inside their homes and offices — carbon monoxide (CO).

8 Jan 2014

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 Health Innovation funding by the European Commission to develop its Graves' disease therapeutic vaccine, including a Phase I first-in-man study in Graves' disease patients.

8 Jan 2014

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Although drugs have been developed that inhibit the imbalance of neurotransmitters in the brain - a condition which causes many brain disorders and nervous system diseases - the exact understanding of the mechanism by which these drugs work has not yet been fully understood.

8 Jan 2014

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Janssen-Cilag International NV today announced the early stopping of PCYC-1112-CA, the Phase 3 study of ibrutinib in the treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, based on the recommendation of an Independent Data Monitoring Committee, which concluded that the study showed a significant difference in progression-free survival as compared to the control, the primary endpoint of the study.

8 Jan 2014

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Oasis Diagnostics Corporation is the recipient of a research award from The Michael J. Fox Foundation for Parkinson's Research to validate OASIS' development of a non-invasive, saliva-based, rapid test for Parkinson's disease detection and diagnosis.

8 Jan 2014

Cancer Treatment Centers of America recognized with Clinical Nutrition Team of Distinction Award

Cancer Treatment Centers of America has been recognized by the American Society for Parenteral and Enteral Nutrition with the organization's "Clinical Nutrition Team of Distinction Award". Members of the CTCA professional staff will be honored by A.S.P.E.N at its Clinical Nutrition Week Conference in Savannah, GA this January 2014. This award is presented to multi-discipline clinical teams that exemplify excellence in interdisciplinary clinical nutrition practice in compliance with A.S.P.E.N. standards, guidelines and values.

8 Jan 2014

Study: Combined medications may improve smoking cessation than single drug therapy

Among cigarette smokers, combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in higher smoking abstinence rates for one outcome but not the other at three and six months; rates were similar at one year, according to a Mayo Clinic study published this month in JAMA.

8 Jan 2014

IQWiG study finds no added benefit of teriflunomide

Teriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

8 Jan 2014

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in the Journal of Nuclear Medicine highlights the potential of newly developed radiopharmaceuticals with benzamide for the imaging of metastases and as a targeted systemic therapy.

8 Jan 2014

Added benefit of dabrafenib not proven

Dabrafenib has been approved in Germany since August 2013 for the treatment of advanced melanoma. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the appropriate comparator therapy.

7 Jan 2014

Landes Bioscience releases special issue on sepsis

A special issue on sepsis has been released by the publisher Landes Bioscience (Austin, TX USA). The articles contained in this special issue of the journal Virulence have been authored by world-class investigators and provide new insights into both the pathogen-related factors and the host defense mechanisms that lead to septic shock and contribute to its resolution or fatal outcome.

7 Jan 2014

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration has accepted and filed for review the company's Biologics License Application for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism.

7 Jan 2014

Blueprint Medicines closes $25 million Series B financing

Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.

7 Jan 2014

Minnesota professor receives Hazelden's Dan Anderson Research Award for hybrid CBT study

Matt G. Kushner, Ph.D., professor of Psychiatry, University of Minnesota (Minneapolis) has earned the latest Dan Anderson Research Award for his study examining the effectiveness of a hybrid cognitive behavioral therapy in the treatment of individuals with co-occurring anxiety disorders and alcohol dependence.

7 Jan 2014

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension.

7 Jan 2014

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease.

7 Jan 2014

ObamaCare can be a costly shift for people suffering with obstructive sleep apnea

Health insurance is a fast changing landscape in the United States with the implementation of ObamaCare, also known as The Affordable Health Care Act. Health insurance companies are doing something called cost shifting where the cost of care gets shifted onto the patients. For people who suffer with obstructive sleep apnea, this is can be a costly shift.

7 Jan 2014

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers from Rice University's Baker Institute for Public Policy and the University of Texas MD Anderson Cancer Center.

7 Jan 2014

Therapy News and Research

Quick tips to avoid carbon monoxide poisoning

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Cancer Treatment Centers of America recognized with Clinical Nutrition Team of Distinction Award

Study: Combined medications may improve smoking cessation than single drug therapy

IQWiG study finds no added benefit of teriflunomide

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

Added benefit of dabrafenib not proven

Landes Bioscience releases special issue on sepsis

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

Blueprint Medicines closes $25 million Series B financing

Minnesota professor receives Hazelden's Dan Anderson Research Award for hybrid CBT study

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

ObamaCare can be a costly shift for people suffering with obstructive sleep apnea

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News